Overview

Apatinib Plus Docetaxel Versus Docetaxel as Second-line Treatment in Advanced Gastric Cancer (AHEAD-301)

Status:
Unknown status
Trial end date:
2019-02-01
Target enrollment:
Participant gender:
Summary
Apatinib plus docetaxel versus docetaxel as second-line treatment in advanced gastric cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Chinese PLA General Hospital
Treatments:
Apatinib
Docetaxel